The careful choice of nanoparticles as targets and in drug delivery routes enhances therapeutic efficacy in cancer. Nanoparticle-Based Drug Delivery in Cancer Treatment discusses nanotechnological developments of interfering RNA-based nanoparticles, delivery vehicles, and validated therapeutic RNAi-molecular target interactions and explains the results of clinical and preclinical trials. The book also gives strategies for universal methods of constructing hybrid organic-inorganic nanomaterials that can be widely applied in the biomedical field. Key Features: Reviews recent advances of nanoparticle-mediated siRNA delivery systems and their application in clinical trials for cancer therapy Focuses on material platforms that establish NPs and both localized and controlled gene silencing Emphasizes the most promising systems for clinical application Surveys progress in nanoparticle-based nanomedicine in cancer treatment Describes the most advanced of the nonviral nanocarriers for delivery of oligonucleotides to malignant blood cancer cells This book is a valuable resource for researchers, professors, and students researching drug delivery, gene carriers, cancer therapy, nanotechnology, and nanomaterials.

Site-specific drug delivery and targeting attracts much research interest from both academia and industry, but because of the many challenges faced in the development of these systems, only a handful of targeted therapies have successfully made it into clinical practice. Focusing on the delivery technologies that utilize both systemic and local routes of administration, Targeted Delivery of Small and Macromolecular Drugs brings together field experts who summarize current progress and discuss novel ideas currently being explored to overcome these challenges. The contributors discuss the most promising strategies for drug targeting and also examine targeted drug delivery platforms and technologies at various stages of clinical and preclinical development, including: Active targeting Nucleic acid delivery and targeting Intracellular/organelle-specific strategies Prodrug strategies Organ or tissue-specific drug delivery Drug-polymer conjugates and micelles Stimuli-responsive systems The book demonstrates why targeted delivery is one of the most exciting contributions pharmaceutical sciences can make to drug therapy.

Biodrug Delivery Systems: Fundamentals, Applications and Clinical Development presents the work of an international group of leading experts in drug development and biopharmaceutical science who discuss the latest advances in biodrug delivery systems and associated techniques. The book discusses components of successful formulation, delivery, and production of biodrugs, which include sophisticated plants and complex processes, a well-trained and knowledgeable staff, and proper quality control. In addition, the authors examine: ADME (Absorption, Metabolism, Distribution, and Elimination of biodrugs) Directing and influencing the successful development of currently marketed best-selling biodrugs Routes of administration Mechanisms of biodrug absorption Alternative possibilities for drug delivery routes Formulationson the market from the perspective of industry personnel involved in biodrug development

For drugs with a narrow therapeutic index, therapeutic drug monitoring methods are essential for patient management. Although immunoassays are commercially available for many drugs and most laboratories use these assays for routine therapeutic monitoring, they have many limitations which hinder their efficacy. Providing practical guidelines for implementing preferred gas and liquid chromatographic methods, Advances in Chromatographic Techniques for Therapeutic Drug Monitoring is a comprehensive reference describing the theory and application of therapeutic drug monitoring in clinical laboratories. Edited by a distinguished authority in the field and containing contributions from a variety of experts, the book discusses preanalytical variables, the pitfalls of immunoassays, tandem mass spectrometry, issues related to pain management and herbal supplements, and therapeutic drug monitoring for a range of medications, including: Anticonvulsants Digitalis Cardioactive drugs Antidepressants Immunosuppressants Anti-cancer drugs Vancomycin and aminoglycosides Antibiotics Antiretroviral drugs Nonnarcotic analgesics Anti-inflammatory drugs Examing older and newer drugs, the book contains detailed discussions on the rationale for therapeutic drug monitoring of each class of drugs, along with their basic pharmacology and toxicology. An extensive list of references is provided at the end of each chapter so that those interested in implementing a new drug assay can find the most appropriate method for the intended drug.

Medicinal Plant Responses to Stressful Conditions discusses the effects of multiple biotic and abiotic stressors on medicinal plants. It features information on biochemical, molecular, and physiological strategies used to mitigate or alleviate detrimental effects of biotic and abiotic stressors. The book contains chapters featuring medicinal plants of importance covering subjects including genomics, functional genomics, metabolomics, phenomics, proteomics, and transcriptomics under biotic and abiotic stress of medicinal plants and their molecular responses. It suggests exogenous application of different types of stimulants to enhance medicinal plant production in such conditions. Features: · Details all aspects of biotic and abiotic stressors in various important medicinal plant species. · Chapters cover evidence-based approaches in the diagnosis and management of medicinal plants under stressful conditions. · Includes information on ways to mitigate effects from high salinity, drought, temperature extremes, waterlogging, wind, high light intensity, UV radiation, heavy metals, or mineral deficiencies. A volume in the Exploring Medicinal Plants series, this book is an essential resource for plant scientists, botanists, environmental scientists, and anyone with an interest in herbal medicine

The pharmaceutical industry recognizes the shift to the use of natural products while also considering the serious concerns that have arisen regarding the claimed efficacy, quality, and safety of these products. This volume showcases how pharmaceutical and nutraceutical compounds from natural products can be used to cure or prevent diseases. The chapters explore the connections between agrochemicals and pharmaceuticals and the use of plants and plant products in the formulation and development of new pharmaceuticals and nutraceuticals.

From Physick to Pharmacology addresses the important, albeit neglected history of the distribution and sale of medicinal drugs in England from the sixteenth to the twenty-first century. The social history of early medicine and the evolution of British retailing are two areas that have attracted considerable attention from academics in recent years. That said, little work has been done either by medical or business historians on the actual retailing of drugs. This book merges the two themes by examining the growth in the retailing of medicinal drugs since late-medieval times. The six academics contributing essays include both medical and business historians who provide an informed and stimulating perspective on the subject. After an introduction setting out the context of drug retailing and surveying the current literature, the volume is arranged in a broadly chronological order, beginning with Patrick Wallis's study of apothecaries and other medical retailers in early modern London. The next chapter, by Louise Hill Curth, looks at the way the distribution network expanded to encompass a range of other retail outlets to sell new, branded, pre-packaged proprietary drugs. Steven King then examines various other ways in which medicines were sold in the eighteenth century, with a focus on itinerant traders. This is followed by pieces from Hilary Marland on the rise of chemists and druggists in the nineteenth century, and Stuart Anderson on twentieth-century community pharmacists. The final essay, by Judy Slinn, examines the marketing and consumption of prescription drugs from the middle of that century until the present day. Taken together, these essays provide a fascinating insight into the changes and continuities of five centuries of drug retailing in England.

This volume sheds new light on the immense potential of medicinal plants for human health from different technological aspects. It presents new research on bioactive compounds in medicinal plants that provide health benefits, including those that have proven especially effective in treating and managing diabetes mellitus and hypertension. It looks at the medicinal properties, antioxidant capacity, and antimicrobial activity of plants and provides scientific evidence on the use of medicinal plants in the treatment of certain diseases. Many of the plants described in the chapters are easily accessible and are believed to be effective with fewer side effects in comparison to modern drugs in the treatment of different diseases.

Market access is the fourth hurdle in the drug development process and the primary driver for global income of any new drug. Without a strategy in place for pricing, showing value for effectiveness and an understanding of the target purchasers' needs, the drug will fail to reach its intended market value. Introduction to Market Access for Pharmaceuticals is based on an accredited course in this area, taken from the European Market Access University Diploma (EMAUD), and is affiliated with Aix Marseille University. Key Features: The first guide to market access for pharmaceuticals based on tested teaching materials Addresses both pharmaceutical and vaccine products Includes case studies and scenarios Covers market access consdierations for Western Europe, the USA, Japan and China Explains the impact the changing healthcare market will have on your product

Microbial Biofilms: Omics Biology, Antimicrobials and Clinical Implications is a comprehensive survey of microbial biofilms and their role in human health and disease with contributions from world renowned experts in molecular microbiology, proteomics, genomics, metabolomics and infectious diseases. The book is intended to serve as a guide for students, as well as a reference for researchers, clinicians and industry professionals. The chapters cover bacterial and fungal microbiomes, and the latest omics techniques organized in a clear and up-to-date manner. One of the highlights of this book is the comprehensive information on "omics of microbial biofilms". The chapters dedicated to metagenomics, proteomics and metabolomics are designed to provide a simple and holistic review of the current knowledge and, the applications of these techniques in the field of microbial biofilms. In addition to introductory chapters on microbial biofilms and their clinical implications, subsequent chapters delve into oral biofilms, their composition, and metagenomic diversity. Thereafter, mechanisms of drug resistance in microbial biofilms are reviewed, as well as the proteomic and metabolomic characterization of this resistance. The book includes a comprehensive discussion of persister cells and host-microbial interactions on mucosal surfaces. Finally, the book concludes with a summary of novel therapeutic approaches for biofilms such as synbiotics and biogenics.

Ethnopharmacology and Biodiversity of Medicinal Plants provides a multitude of contemporary views on the diversity of medicinal plants, discussing both their traditional uses and therapeutic claims. This book emphasizes the importance of cataloging ethnomedical information as well as examining and preserving the diversity of traditional medicines. It also discusses the challenges present with limited access to modern medicine and the ways in which research can be conducted to enhance these modern practices. The book also explores the conservation procedures for endangered plant species and discusses their relevance to ethnopharmacology. Each chapter of this book relays the research of experts in the field who conducted research in diverse landscapes of India, providing a detailed account of the basic and applied approaches of ethnobotany and ethnopharmacology. The book reviews multiple processes pertaining to medicinal plants, such as collecting the traditional therapeutic values and validation methods. It also explores developments in the field such as the diversity and medicinal potential of unexplored plant species and applications in drug formulation to fight against anti-microbial resistance (AMR).

This valuable new book, Handbook of Research on Medicinal Chemistry: Innovations and Methodologies, presents some of the latest advancements in the various fields of combinatorial chemistry, drug discovery, biochemical aspects, pharmacology of medicinal agents, current practical problems, and nutraceuticals. The editors keep the drug molecule as the central component of the volume and aim to explain the associated features essential to exhibiting pharmacological activity. With a unique combination of chapters in biology, clinical aspects, biochemistry, synthetic chemistry, medicine and technology, the volume provides broad exposure to the essential aspect of pharmaceuticals. The volume many important aspects of medicinal chemistry, including techniques in drug discovery pharmacological aspects of natural products chemical mediators: druggable targets advances in medicinal chemistry The field of medicinal chemistry is growing at an unprecedented pace, and this volume takes an interdisciplinary approach, covering a range of new research and new practices in the field. The volume takes into account the latest therapeutic guidelines put forward by the World Health Organization and the U.S Food and Drug Administration.. Topics include: drug design drug discovery natural products and supplements and nutraceuticals pharmaceutical approaches to sexual dysfunction drug resistance parasites new natural compounds and identification of new targets stereochemistry aspects in medicinal chemistry common drug interactions in daily practices Handbook of Research on Medicinal Chemistry: Innovations and Methodologies will be a valuable addition to the bookshelves of pharmaceutical scientists and faculty as well as for industry professionals.

The Royal College of Emergency Medicine (RCEM) has implemented a new 2021 curriculum, with a new Single Best Answer (SBA) paper for the fellowship examination. Featuring 200 Single Best Answer questions and answers, this text is the first on the market to help prepare for this new examination. Mapped to the curriculum, this book covers core areas such as cardiology, environmental emergencies, mental health, toxicology, trauma, resuscitation and quality improvement. All of the answers are fully referenced to up-to-date guidelines and research, to allow for further reading. This is an essential text for postgraduate doctors in Emergency Medicine studying for the Fellowship of the Royal College of Emergency Medicine (FRCEM) SBA examination.

Today, more than ever, the pharmacist is a full-member of the health team and many of the pharmacist's patients are using a host of other devices from various specialty areas of medicine and surgery. Medical Devices for Pharmacy and Other Healthcare Professions presents a comprehensive review of most devices that pharmacists and pharmacy personnel encounter during practice. The devices covered are relevant to pharmacists working in various work settings from hospitals, community pharmacies, and health insurance sector, to regulatory bodies, academia, and research institutes. Even if a pharmacist does not come across each of these devices on a regular basis, the book is a valuable reference source for those occasions when information is needed by a practitioner, and for instructing interns and residents. The book discusses devices needed for special pharmaceutical services and purposes such as residential care homes and primary care based with GPs, pharmacy-based smoking cessation services, pharmacy-based anticoagulant services, pain management and terminal care, medication adherence and automation in hospital pharmacy. Additional features include: Provides information on devices regarding theory, indications, and procedures concerning use, cautions, and place, in therapy. Assists pharmacists in understanding medical devices and instructing patients with the use of these devices. Focuses on providing the available evidence on effectiveness and cost-effectiveness of devices and the latest information in the particular field. Other healthcare providers interested in medical devices or involved in patients care where medical devices represent part of the provided care would benefit from the book.

Reliably optimizing a new treatment in humans is a critical first step in clinical evaluation since choosing a suboptimal dose or schedule may lead to failure in later trials. At the same time, if promising preclinical results do not translate into a real treatment advance, it is important to determine this quickly and terminate the clinical evaluation process to avoid wasting resources. Bayesian Designs for Phase I-II Clinical Trials describes how phase I-II designs can serve as a bridge or protective barrier between preclinical studies and large confirmatory clinical trials. It illustrates many of the severe drawbacks with conventional methods used for early-phase clinical trials and presents numerous Bayesian designs for human clinical trials of new experimental treatment regimes. Written by research leaders from the University of Texas MD Anderson Cancer Center, this book shows how Bayesian designs for early-phase clinical trials can explore, refine, and optimize new experimental treatments. It emphasizes the importance of basing decisions on both efficacy and toxicity.

It is essential to minimize damage to normal tissues during radiation therapy and many strategies have been employed in finding the best methods for radioprotection. This book integrates chemical, biological, and clinical perspectives on these strategies and developments, providing a comprehensive treatise. It emphasizes new concepts in radioprotection, aiming to inspire further basic science and clinical progress in radioprotector research. Radioprotectors: Chemical, Biological, and Clinical Perspectives includes the following topics:
o Early research on radioprotectors
o WR-2721, an aminothiol prodrug, as a radioprotector
o New results with naturally occurring thiols
o Nitroxides as effective radioprotectors in vitro and in vivo
o Radioprotection observed with radical scavengers or antioxidants
o Bone marrow radioprotection with cytokines and biological modifiers
o Multiple mechanisms of altering radiation response by eicosanoids
o Vascular response to radiation and the importance of vascular damage to normal tissue
o Modifiers of radiation-induced apoptosis
o Survey of clinical trials with radioprotectors
Radiation biologists and oncologists, cancer researchers, and toxicologists will benefit from the findings discussed and strategies for future research.

There is a wealth of published research on the health-promoting effects of green tea and its various components including polyphenols. Green Tea Polyphenols: Nutraceuticals of Modern Life presents a collection of global findings on the numerous health benefits of green tea polyphenols, confirming their position as healthy functional ingredients. With chapters contributed by experts in the field of green tea science and the inclusion of extensive references, this book provides an authoritative volume that can be used to guide researchers, scientists, and regulatory bodies. Each chapter previews a specific theme and highlights recent research and development conducted in the field. The book begins with the history, processing, and features of green tea. It then describes the chemical composition and biochemical and physicochemical characteristics, followed by a discussion of the properties of green tea polyphenols, including metabolism, bioavailability, and safety. The subsequent chapters deal with the numerous health benefits associated with consumption of green tea polyphenols. These include benefits related to cancer risk and prevention, cardiovascular disease, protection of internal organs, diabetes and weight management, bone and muscle health, allergies, oral care, inflammation, and gut health. The book addresses the nutrigenomics and proteomics of poyphenols. It also examines food and nonfood applications of green tea polyphenols, such as extracts, supplements, and skin and hair cosmetic products, demonstrating both therapeutic and functional health benefits. This book brings together a wide array of data on green tea polyphenols, providing a greater understanding of them and insight into their effects on human health, and their applications and commercial potential.

Hein and Moon take up a serious problem of contemporary global governance: what can be done when international trade rules prevent the realization of basic human rights? Starting in the 1990s, intellectual property obligations in trade agreements required many developing countries to begin granting medicines patents, which often rendered lifesaving drugs unaffordable. At stake was the question of what priority would be given to health-particularly of some of the world's poorest people-and what priority to economic interests, particularly those of the most powerful states and firms. This book recounts the remarkable story of the access to medicines movement. The authors offer an explanation for how the informal, but powerful norm that every person should have access to essential medicines emerged after a decade of heated political contestation and against long odds. They also explore the stability and scope of the norm. Finally, the book examines the limitations of informal norms for protecting human rights, and when renewed focus on changing formal norms is warranted.

The purpose of risk assessment is to support science-based decisions about how to solve complex societal problems. The problems we face in the twenty-first century have many social, political, and technical complexities. Environmental risk assessment in particular is of increasing importance as a means of seeking to address the potential effects of chemicals in the environment in both the developed and developing world. Environmental Risk Assessment: A Toxicological Approach examines various aspects of problem formulation, exposure, toxicity, and risk characterization that apply to both human health and ecological risk assessment. The book is aimed at the next generation of risk assessors and students who need to know more about developing, conducting, and interpreting risk assessments. It delivers a comprehensive view of the field, complete with sufficient background to enable readers to probe for themselves the science underlying the key issues in environmental risk. Written in an engaging and lively style by a highly experienced risk assessment practitioner, the text: Introduces the science of risk assessment-past, present, and future Covers problem formation and the development of exposure factors Explains how human epidemiology and animal testing data are used to determine toxicity criteria Provides environmental sampling data for conducting practice risk assessments Examines the use of in vitro and 'omics methods for toxicity testing Describes the political and social aspects of science-based decisions in the twenty-first century Includes fully worked examples, case studies, discussion questions, and links to legislative hearings Readers of this volume will not only learn how to execute site-specific human health and ecological risk assessments but also gain a greater understanding of how science is used in deciding environmental regulations.

The fifth edition of this popular textbook continues to provide a solid foundation of pharmacological knowledge for all those working in anaesthesia and intensive care. The content has been thoroughly revised to include expanded chapters with clearer figures, ensuring readers are kept abreast of the ever-changing landscape of clinical pharmacology. Conveniently divided into four sections covering the basic principles of pharmacology, core drugs in anaesthetic practice, cardiovascular drugs, and other important drugs and complemented by new diagrams, tables and chemical formulae to facilitate learning. All four chapters on core drugs in anaesthetic practice have been updated along with others exploring applied pharmacokinetic models, antimicrobials, and drugs used in diabetes. An ideal aid to study and practice for junior and trainee anaesthetists and intensive care specialists preparing for exams. Also an invaluable resource for theatre practitioners, ICU nurses and physicians working in areas that demand a solid knowledge of pharmacology.

The first edition of Bioactive Compounds from Natural Sources was published in a period of renewed attention to biologically active compounds of natural origin. This trend has continued and intensified-natural products are again under the spotlight, in particular for their possible pharmacological applications. Largely focusing on natural products as lead compounds in drug discovery, Bioactive Compounds from Natural Sources, Second Edition: Natural Products as Lead Compounds in Drug Discovery is actually a completely new volume containing surveys of selected recent advances in an interdisciplinary area covering chemistry of natural products, medicinal chemistry, biochemistry, and other related topics. Written by some of the most reputed scientists in the field, this second edition includes new chapters from authors who contributed to the first edition as well as many chapters compiled by new authors. Introducing the reader to strategies and methods in the search for bioactive natural products, this book covers topics including: Natural sources of bioactive compounds such as aquatic cyanobacteria, filamentous fungi, and tropical plants, The tremendous potentiality of metabolic engineering of natural products biosynthesis The contribution of emerging or developing technologies to the study of bioactive natural compounds, namely computational methods and circular dichroism The potential of natural or natural-derived compounds for specific therapeutic applications: treatment of viral diseases, regulation of hypoxia-inducible factor, antimalarials, modulation of angiogenesis, and antitumor and wound-healing activity Selected examples of natural product families and related synthetic analogues, namely polyphenols and campthotecins Compiled for researchers and Ph.D. students working in interdisciplinary fields, this book will also be appreciated by readers without a background in chemistry interested in bioactive natural products, their biological and pharmacological properties, and their possible use as chemopreventive or chemotherapeutic agents. Conversely, the biological and pharmacological data and methods are accessible by chemists.

Written by John Lidstone and Janice MacLennan, the second edition of Marketing Planning for the Pharmaceutical Industry became accepted as the bible for the industry. In this new companion book Janice MacLennan picks up two of the themes touched on in Marketing Planning - market segmentation and branding, and the inter-relationship between these two - and with this book makes them key topics for discussion. Brand Planning for the Pharmaceutical Industry begins by exploring what branding is and why it is of importance, particularly to the pharmaceutical sector. The book then goes on to show how branding can be integrated into the early stages of the commercialization process for new products, both in theory and in the 'real' world. The book provides a step-by-step guide to brand planning, using market segmentation as the starting point. The book is split into two parts, the first dealing comprehensively with brand planning for products yet to get to the market, with the second part applying the same process to products that are already on the market. Both parts are extremely pragmatic, full of pertinent examples and insights from the pharmaceutical industry, and are directly applicable to your own brand planning. Brand Planning for the Pharmaceutical Industry concludes by confronting the problems that organizations are likely to have in actually making brand planning an integral part of their work and presents strategies for dealing with them.

There is an increasing interest in plants of the Moringa genus used as a source of phytochemicals with biopharmaceutical potential, as a functional ingredient in many products and as an additive in poultry feeding stocks. Biological and Pharmacological Properties of the Genus Moringa is the first publication to comprehensively assess the latest research on Moringa studies. This book reviews recent studies covering the botanical, agronomical, genomic, biotechnological, and ethnopharmacological aspects. It presents specialized work in a user-friendly way that will appeal to undergraduates, graduates and researchers primarily in ethnopharmacology, functional foods and with a linkage to veterinary treatments. Key Features: Describes the ethnopharmacological and ethnobotanical use of plants from all Moringa species Presents recent information that will be helpful for the future development of biopharmaceuticals Reviews the phytochemical content from all Moringa species Assesses the potential of all Moringa species as a functional ingredient

Building on the success of the previous editions, the Textbook of Drug Design and Discovery, Fifth Edition, has been thoroughly revised and updated to provide a complete source of information on all facets of drug design and discovery for students of chemistry, pharmacy, pharmacology, biochemistry, and medicine. The information is presented in an up-to-date review form with an underlying and fundamental focus on the educational aspects. Beginning with an introduction to drug design and discovery, the first eight chapters cover molecular recognition, ligand-based drug design, and biostructure-based drug design. The authors also discuss drug-like properties and decision making in medicinal chemistry, chemical biology, natural products in drug discovery, and in vivo imaging in drug discovery. The middle six chapters provide an overview of peptide and protein drug design, prodrugs in drug design and development, and enzyme inhibitors. The authors also go through receptors (structure, function, and pharmacology), ion channels (structure and function), and neurotransmitter transporters (structure, function, and drug binding). The following chapters address important neurotransmitter systems, GABA and glutamic acid receptors and transporter ligands, acetylcholine, histamine, dopamine and serotonin, and opioid and cannabinoid receptors. The book concludes with an examination of neglected diseases, anticancer agents, tyrosine kinase receptors, and antibiotics.

First Published in 1998. Routledge is an imprint of Taylor & Francis, an informa company.